Spark eyes installment plan for $1M gene therapy; Pharma sales to hit $1.3T by 2018, report says;

> As a pricey gene therapy for blindness nears the market--some expect a cost of $1 million--its maker, Spark Therapeutics, is working with payers on long-term payment options, including pay-for-performance models. Report

> Global pharma sales are projected to grow to $1.3 trillion by 2018, Thomson Reuters says, as more brand-new drugs win approval, particularly in cancer. Report

> Me-too drugs may be due for an image overhaul now that competitive rivalries are helping bring down prices in some areas. Report

> Specialty pharmacy Diplomat ($DPLO) signed up to dispense AstraZeneca's ($AZN) cancer treatment Iressa, which recently won FDA approval for first-line, non-small cell lung cancer treatment. Report

> GlaxoSmithKline ($GSK) rolled out a new Sensodyne campaign in India. Report

> NattoPharma and TG Montgomery partnered up to take the vitamin brand MenaQ7 into Sweden. Report

> Turing Pharmaceuticals bought marketing rights to Daraprim (pyrimethamine) from Impax Laboratories ($IPXL) in a focus on toxoplasmosis and other infectious diseases. Report

And Finally... Roche ($RHHBY) brought in 100 European students for a music and drama festival to explore the intersection of science and music. Release

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.